<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230071</url>
  </required_header>
  <id_info>
    <org_study_id>P2017-03-BDY-03-V03</org_study_id>
    <nct_id>NCT03230071</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia</brief_title>
  <official_title>Efficacy and Safety of Twice Daily TMBCZG in Mild to Moderate Vascular Dementia: Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Union pharmaceutical factory II</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Compete Medical Technology Development Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dongzhimen Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a 24-week multicentre, double-blind, placebo-controlled phase Ⅱa trial with
      4 treatment arms in China. Participants aged 55-80 years will be randomized to TMBCZG-high
      dose(84mg per day), TMBCZG- medium dose(56mg per day), TMBCZG- low dose(28mg per day) or to
      placebo. The primary endpoint will be VADAS-Cog and CDR-SB. Secondary outcomes included
      changes in MMSE and ADL. Patients' safety will be assessed by recording of adverse events,
      clinical examinations, electrocardiography and laboratory tests. The patients, caregivers,
      and investigators will be blinded to the treatment allocations.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular Dementia Assessment Scale-cognitive subscale(VADAS-Cog)</measure>
    <time_frame>baseline, 4-week, 12-week, 24-week and 28-week.</time_frame>
    <description>Change from baseline to end of double-blind treatment of VADAS-Cog.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Dementia Rating-Sum of Boxes (CDR-SB)</measure>
    <time_frame>baseline, 4-week, 12-week, 24-week and 28-week.</time_frame>
    <description>Change from baseline to end of double-blind treatment of CDR-SB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE)</measure>
    <time_frame>baseline, 4-week, 12-week, 24-week and 28-week.</time_frame>
    <description>Change from baseline to end of double-blind treatment of MMSE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living (ADL)</measure>
    <time_frame>baseline, 4-week, 12-week, 24-week and 28-week.</time_frame>
    <description>Change from baseline to end of double-blind treatment of ADL.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMBCZG-high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMBCZG-medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMBCZG-low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMBCZG</intervention_name>
    <description>0.1g per pill which contains 14mg TMBCZG</description>
    <arm_group_label>TMBCZG-high dose</arm_group_label>
    <arm_group_label>TMBCZG-medium dose</arm_group_label>
    <arm_group_label>TMBCZG-low dose</arm_group_label>
    <other_name>TianMaBianChunZhiGanPian</other_name>
    <other_name>TianMaYouJiDuoSuanBianZhiGanPian(TMYJDSBZG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.1g per pill which contains 0mg TMBCZG</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TMBCZG-medium dose</arm_group_label>
    <arm_group_label>TMBCZG-low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients meeting the clinical diagnosis of probable vascular dementia(VaD) established
             according to the National Institute of Neurological Disorders and Stroke and the
             Association Internationale pour la Recherche et l'Enseignement en Neurosciences
             (NINDS-AIREN)were eligible to participate:

               1. Dementia defined by clinical core criteria,

               2. Cerebrovascular disease, defined by history of stroke, as well as multiple basal
                  ganglia and white matter lacunes, or extensive periventricular white matter
                  lesions( excluded medial temporal lobe atrophy or other special image),

               3. A relationship between dementia and Cerebrovascular disease, manifested or
                  inferred by the presence of one or more of the following: (a) onset of dementia
                  within 3 months following a recognized stroke; (b) abrupt deterioration in
                  cognitive functions; or fluctuating, stepwise progression of cognitive deficits.

          -  Mild to Moderate Dementia with MMSE score of ≤26 and ≥11;

          -  Aged ≥55 and ≤80 years old in both gender;

          -  Weighing of ≥45kg and ≤90kg;

          -  Adequate vision and hearing ability to complete all study tests;

          -  With a stable caregiver.

          -  Have a certain level of language competence (can read simple articles and write simple
             sentences);

          -  Informed consent, signed informed consent by legal guardian.

        Exclusion Criteria:

          -  A medical history of other dementia types, like mixed dementia, Alzheimer's disease,
             frontotemporal dementia, Parkinson's disease dementia, dementia with Lewy bodies,
             Huntington disease, et al;

          -  Subdural hematoma, traffic hydrocephalus, brain tumor, thyroid disease,vitamin
             deficiency or other diseases which can lead to cognitive impediment;

          -  Major depression (HAMD≥17) or major anxious(HAMA≥12);

          -  Subject can't complete related test due to severe neurologic deficits, such as
             hemiplegia, aphasia, audio-visual disorder and so forth;

          -  Severe cardiovascular disease(severe arrhythmia, myocardial infarction within 3
             months, New York Heart Association Functional Classification III-IV, systolic
             pressure≥180mmHg or ≤90mmHg);

          -  Severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase
             is more than 1.5 times the upper limit of normal, or serum creatinine is more than the
             upper limit of normal);

          -  Uncontrolled diabetes(glycosylated hemoglobin is more than 2 times the upper limit of
             normal);

          -  Asthma, chronic obstructive pulmonary disease, multiple neuritis, myasthenia gravis
             and muscle atrophy;

          -  Severe indigestion, gastrointestinal obstruction, gastric and duodenal ulcers and
             other gastrointestinal disorders that can affect drug absorption;

          -  A medical history of epileptic history, glaucoma, alcoholism, or psycho-substance
             abuse;

          -  Subject has been taking cholinesterase inhibitors, memantine, nimodipine or herbal
             medicine with function of improving cognition in the past one month;

          -  Use of sympathomimetic or antihistamines drugs within 48h before assessment;

          -  Allergic constitution or allergic reactions to experimental drug;

          -  According to the assessment of the investigator, subject cann't complete the study due
             to poor compliance or other reasons;

          -  Subject is participating in other clinical trials or participated in the past 1 month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JinZhou Tian, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dongzhimen Hospital,Beijing University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JinZhou Tian, MD,PhD</last_name>
    <phone>86-10-84013380</phone>
    <email>jztian@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Shi, MD</last_name>
    <email>shijing87@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongzhimen Hospital ,Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongzhimen Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Jinzhou Tian</investigator_full_name>
    <investigator_title>vice-president</investigator_title>
  </responsible_party>
  <keyword>Herbal therapy</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Vascular Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

